Pharmaceutical, Medical Device Industries Concerned About Sharfstein As FDA Deputy Director

Main Category: Regulatory Affairs / Drug Approvals
Also Included In: Pharma Industry / Biotech Industry;  Medical Devices / Diagnostics
Article Date: 20 Mar 2009 - 6:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


The pharmaceutical and medical device industries have praised the nomination of former New York City Health Commissioner Margaret Hamburg as FDA commissioner, but they are "nervous in varying degrees" about the nomination of Baltimore Health Commissioner Joshua Sharfstein as principal deputy commissioner of the agency, CongressDaily reports.

According to one lobbyist, Sharfstein likely "will have a certain amount of autonomy on pharmaceuticals and medical devices," as Hamburg likely will focus on food safety and tobacco regulation. The lobbyist added, "Companies are clearly going to get more scrutiny" under Sharfstein.

As a former staffer for House Energy and Commerce Committee Chair Henry Waxman (D-Calif.), who "has been tough on drug companies," Sharfstein "has a long and sometimes contentious history with the pharmaceutical industry," CongressDaily reports. "Sharfstein has carried the torch on many of his boss's public health priorities" -- such as efforts to limit off-label use of medications and gifts from pharmaceutical companies to physicians -- and he "could play a key role implementing 2007 FDA legislation" that requires pharmaceutical companies to develop risk evaluation and mitigation strategies, according to CongressDaily.

Peter Pitts, a former FDA associate commissioner for external affairs and co-founder of the Center for Medicine in the Public Interest, said that many of the concerns about Sharfstein raised by the pharmaceutical and medical device industries are unfounded. "I don't think you'll see more strident regulations," he said, adding, "I think you'll see a more effective way to use existing regulation" (Edney, CongressDaily, 3/18).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Article adapted by Medical News Today from original press release.
Visit our regulatory affairs / drug approvals section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kaiser. "Pharmaceutical, Medical Device Industries Concerned About Sharfstein As FDA Deputy Director." Medical News Today. MediLexicon, Intl., 20 Mar. 2009. Web.
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/143035.php>

APA
Kaiser. (2009, March 20). "Pharmaceutical, Medical Device Industries Concerned About Sharfstein As FDA Deputy Director." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/143035.php.

Please note: If no author information is provided, the source is cited instead.


Regulatory Affairs / Drug Approvals

Most Popular Articles



Follow Our Regulatory Affairs News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Regulatory Affairs / Drug Approvals Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »